Description

Donormil (doxylamine succinate) Coated Tablets 15 mg. №30 Vial

Ingredients

Active ingredient: Doxylamine succinate 15 mg per coated tablet.

Dosage

Recommended dosage: Take 1 tablet orally before bedtime with water. Do not exceed the recommended dose.

Indications

Donormil tablets are indicated for the short-term treatment of insomnia characterized by difficulty falling asleep.

Contraindications

Do not use Donormil tablets if you are allergic to doxylamine succinate or if you have narrow-angle glaucoma, severe urinary retention, or severe liver disease.

Directions

Take Donormil tablets exactly as directed by your healthcare provider. Read the medication guide provided with the product for instructions.

Scientific Evidence

Doxylamine succinate, the active ingredient in Donormil tablets, is an antihistamine with sedative properties. Studies have shown that doxylamine succinate can effectively improve sleep onset and quality in individuals with insomnia. Research published in the Journal of Clinical Sleep Medicine demonstrated the efficacy of doxylamine succinate in reducing the time taken to fall asleep and increasing total sleep time.

Additional Information

• Storage: Store Donormil tablets at room temperature away from moisture and heat.
• Side effects: Common side effects may include drowsiness, dry mouth, and blurred vision.
• Warnings: Avoid alcohol while taking Donormil tablets as it may increase drowsiness.

Pharmacological Effects: Doxylamine succinate exerts its sedative effects by antagonizing the action of histamine, a neurotransmitter involved in wakefulness. By blocking histamine receptors in the brain, doxylamine promotes drowsiness and aids in the initiation and maintenance of sleep.

Clinical Trials: Clinical trials have demonstrated the efficacy of doxylamine succinate in improving sleep parameters in patients with insomnia. A study published in the Journal of Sleep Research found that doxylamine succinate significantly reduced the time to fall asleep and improved sleep quality compared to a placebo.